Published in Blood on October 01, 1983
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J (1993) 1.46
CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci (2005) 1.06
Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest (1986) 1.00
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol (2014) 1.00
Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol (1992) 0.99
Antibody therapy for chronic lymphocytic leukemia. Semin Hematol (2008) 0.95
Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95
Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models. J Neuroimmunol (2014) 0.93
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol (1994) 0.89
NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. Bone Marrow Res (2012) 0.89
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. Bone Marrow Transplant (2014) 0.85
Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. Clin Exp Immunol (1987) 0.84
Characterizing the human hematopoietic CDome. Front Genet (2014) 0.84
New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci (2010) 0.84
Current results with orthotopic liver grafting in Cambridge/King's College Hospital series. Br Med J (Clin Res Ed) (1985) 0.84
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biol (2016) 0.83
Graft-versus-host disease: a review. J R Soc Med (1987) 0.82
Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease. Clin Exp Immunol (2006) 0.82
Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. J Hematol Oncol (2008) 0.80
Immune regulation by CD52-expressing CD4 T cells. Cell Mol Immunol (2013) 0.80
Bone marrow T cell colony-forming cells: studies of their origin and use in monitoring T cell-depleted bone marrow grafts. Clin Exp Immunol (1985) 0.79
The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface. PLoS One (2014) 0.79
Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurotherapeutics (2011) 0.78
The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant (2009) 0.78
Changes in plasma beta 2 microglobulin concentrations after allogeneic bone marrow transplantation. J Clin Pathol (1987) 0.77
Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Ther Adv Chronic Dis (2013) 0.77
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther (2010) 0.77
A modern Cosmas and Damian: Sir Roy Calne and Thomas Starzl receive the 2012 Lasker~Debakey Clinical Medical Research Award. J Clin Invest (2012) 0.76
Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression. Leukemia (2016) 0.75
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol (2012) 0.75
Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab. Neuropsychiatr Dis Treat (2015) 0.75
Advances in the applications of monoclonal antibodies in clinical oncology. Abstracts. Br J Cancer (1984) 0.75
Graft versus host diseases: new versions of old problems? Br Med J (Clin Res Ed) (1985) 0.75
Advances in haematological pharmacotherapy in 21st century. Indian J Hematol Blood Transfus (2010) 0.75
Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. MAbs (2016) 0.75
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag (2017) 0.75
Promising approaches in acute leukemia. Invest New Drugs (2000) 0.75
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature (1988) 13.21
Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science (1999) 11.96
The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci (1966) 9.68
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
A family of cytokine-inducible inhibitors of signalling. Nature (1997) 9.22
Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J (1987) 7.45
Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med (1980) 5.80
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev (1995) 5.51
"Infectious" transplantation tolerance. Science (1993) 4.98
Reshaping human antibodies for therapy. Nature (1988) 4.82
Antigen-specific T-cell factor in cell cooperation. Mapping within the I region of the H-2 complex and ability to cooperate across allogeneic barriers. J Exp Med (1975) 4.64
Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med (1992) 4.54
The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood (1986) 4.47
Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature (1984) 4.46
Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A (1998) 4.38
Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo. Br J Haematol (1970) 4.32
Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature (1984) 4.29
SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell (1999) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A (1994) 4.19
Studies on the nature of polysomes. Biochem J (1964) 4.18
The granulocyte-macrophage colony-stimulating factors. Science (1985) 4.13
Antigen-specific T-cell factor in cell cooperation: physical properties and mapping in the left-hand (K) half of H-2. J Exp Med (1974) 4.10
Two genes in the major histocompatibility complex control immune response. Nature (1975) 4.08
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A (1999) 3.91
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem (1977) 3.74
Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A (1995) 3.47
Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A (1999) 3.45
Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor. EMBO J (1985) 3.30
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood (1996) 3.14
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content. J Natl Cancer Inst (1969) 3.06
Studies on colony formation in vitro by mouse bone marrow cells. II. Action of colony stimulating factor. J Cell Physiol (1970) 3.05
Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem (1983) 2.97
The nature and action of granulocyte-macrophage colony stimulating factors. Blood (1980) 2.94
SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol (2000) 2.87
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J (1999) 2.80
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A (1998) 2.79
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A (1996) 2.68
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A (2000) 2.58
Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci U S A (1996) 2.57
Expression of a hemopoietic growth factor cDNA in a factor-dependent cell line results in autonomous growth and tumorigenicity. Cell (1985) 2.55
Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin. Proc Natl Acad Sci U S A (1977) 2.55
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A (1998) 2.48
Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1986) 2.45
Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors. J Immunol (1983) 2.44
Growth of B-lymphocyte colonies in vitro. J Exp Med (1975) 2.41
Growth of mouse megakaryocyte colonies in vitro. Proc Natl Acad Sci U S A (1975) 2.38
Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell (1985) 2.36
Acute antigen-induced elevation of serum colony stimulating factor (CFS) levels. Immunology (1971) 2.28
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet (1988) 2.28
Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer (2012) 2.26
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood (1986) 2.26
Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp Hematol (1987) 2.25
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood (1988) 2.24
Growth of B lymphocyte colonies in vitro from mouse lymphoid organs. Nature (1975) 2.24
Colony formation in vitro by myelomonocytic leukemic cells. J Natl Cancer Inst (1969) 2.21
A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor. EMBO J (1989) 2.13
Routine quantitative analysis of brain and cerebrospinal fluid spaces with MR imaging. J Magn Reson Imaging (1992) 2.11
Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A (2001) 2.09
The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. Eur J Immunol (1997) 2.08
Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood (1999) 2.06
Resolution and purification of three distinct factors produced by Krebs ascites cells which have differentiation-inducing activity on murine myeloid leukemic cell lines. J Biol Chem (1988) 2.05
Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells. Blood (1977) 2.05
Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors. Blood (1979) 2.05
Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect Immun (1988) 2.04
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Subunit promiscuity among hemopoietic growth factor receptors. Cell (1991) 2.03
Colony formation by human T lymphocytes in agar medium. Clin Exp Immunol (1977) 2.03
Production of colony-stimulating factor in mitogen-stimulated lymphocyte cultures. J Immunol (1974) 2.02
Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci U S A (1995) 1.97
Colony formation in agar by multipotential hemopoietic cells. J Cell Physiol (1979) 1.96
The structure and expression of the murine gene encoding granulocyte-macrophage colony stimulating factor: evidence for utilisation of alternative promoters. EMBO J (1985) 1.95
Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci U S A (1998) 1.95
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82